Protara Therapeutics (NASDAQ:TARA) Given New $30.00 Price Target at Oppenheimer

Protara Therapeutics (NASDAQ:TARA) had its price target lifted by Oppenheimer from $26.00 to $30.00 in a report published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Separately, HC Wainwright restated a buy rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, April 8th.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.05 on Monday. The business’s 50-day moving average is $3.76 and its two-hundred day moving average is $2.47. The company has a market capitalization of $34.86 million, a P/E ratio of -0.85 and a beta of 1.71. Protara Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Wednesday, March 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.13. Analysts forecast that Protara Therapeutics will post -3.56 EPS for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.